{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:09Z","timestamp":1792265049524,"version":"4.4.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Anti-programmed cell death-1 (anti-PD1) antibodies are currently the first-line treatment for patients with metastatic <jats:italic toggle=\"yes\">BRAF<\/jats:italic> wild-type melanoma, alone or combined with the anti-CTLA4 monoclonal antibody, ipilimumab. To date, data on safety and the outcomes of patients treated with the anti-PD1 monoclonal antibodies, pembrolizumab (PB), or nivolumab, combined with stereotactic radiosurgery (SRS), for melanoma brain metastases (MBM) are scarce. We retrospectively reviewed all patients with MBM treated with PB combined with SRS between 2012 and 2015. The primary endpoint was neurotoxicity. The secondary endpoints were local, distant intracranial controls and overall survival (OS). Among 74 patients with MBM treated with SRS, 25 patients with a total of 58 MBM treated with PB combined with SRS within 6 months were included. Radiation necrosis, occurring within a median time of 6.5 months, was observed for four MBM (6.8%) in four patients. No other significant SRS-related adverse event was observed. After a median follow-up of 8.4 months, local control was achieved in 46 (80%) metastases and 17 (68%) patients. Perilesional oedema and intratumour haemorrhage appearing or increasing after SRS were associated with local progression (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). The median OS was 15.3 months (95% confidence interval: 4.6\u201326). The timing between SRS and PB administration did not seem to influence the risk of radiation necrosis, intracranial control or OS. SRS combined with PB was well tolerated and achieved local control in 80% of the lesions. Prolonged OS was observed compared with that currently yielded in this population of patients. Prospective studies are required to explore further the optimal ways to combine immunotherapy and SRS.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000413","type":"journal-article","created":{"date-parts":[[2018,1,21]],"date-time":"2018-01-21T02:00:22Z","timestamp":1516500022000},"page":"111-119","source":"Crossref","is-referenced-by-count":56,"title":["Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases"],"prefix":"10.1097","volume":"28","author":[{"given":"Charlee","family":"Nardin","sequence":"first","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mateus","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Texier","sequence":"additional","affiliation":[{"name":"Biostastistics and Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lanoy","sequence":"additional","affiliation":[{"name":"Biostastistics and Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Hibat-Allah","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Dhermain","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","article-title":"Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients","volume":"77","author":"Sperduto","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"R7-20230902","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R8-20230902","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.rpor.2015.12.001","article-title":"Current treatment options of brain metastases and outcomes in patients with malignant melanoma","volume":"21","author":"Nowak-Sadzikowska","year":"2016","journal-title":"Rep Pract Oncol Radiother"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article","volume":"114","author":"Liew","year":"2011","journal-title":"J Neurosurg"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","article-title":"Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma","volume":"31","author":"Anker","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","article-title":"Vemurafenib and radiosensitization","volume":"149","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"key":"R16-20230902","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"key":"R17-20230902","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur J Cancer"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3174\/ajnr.A1362","article-title":"Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging","volume":"30","author":"Barajas","year":"2009","journal-title":"Am J Neuroradiol"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"399","DOI":"10.14694\/EdBook_AM.2013.33.399","article-title":"Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases","author":"Ramakrishna","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R24-20230902","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R25-20230902","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R26-20230902","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20230902","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R28-20230902","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.2147\/OTT.S119428","article-title":"BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy","volume":"9","author":"Chowdhary","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R29-20230902","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/bjc.2017.142","article-title":"Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases","volume":"116","author":"Parakh","year":"2017","journal-title":"Br J Cancer"},{"key":"R30-20230902","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"R31-20230902","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"key":"R32-20230902","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"R33-20230902","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J Neurooncol"},{"key":"R34-20230902","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11060-016-2072-6","article-title":"Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases","volume":"127","author":"Wolf","year":"2016","journal-title":"J Neurooncol"},{"key":"R35-20230902","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"R36-20230902","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1227\/01.NEU.0000255342.10780.52","article-title":"Gamma knife radiosurgery in the management of malignant melanoma brain metastases","volume":"60","author":"Mathieu","year":"2007","journal-title":"Neurosurgery"},{"key":"R37-20230902","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"R38-20230902","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"key":"R39-20230902","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2017.03.030","article-title":"The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases","volume":"98","author":"Sperduto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201804000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:23:43Z","timestamp":1693625023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201804000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000413","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}